Multimodal selenium nanoshell-capped Au@mSiO(2) nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer
- Title
- Multimodal selenium nanoshell-capped Au@mSiO(2) nanoplatform for NIR-responsive chemo-photothermal therapy against metastatic breast cancer
- Author
- 최한곤
- Keywords
- POLYELECTROLYTE COMPLEX MICELLES; HYBRID NANOPARTICLES; GOLD NANOPARTICLES; DRUG-DELIVERY; CHEMOTHERAPY; DOXORUBICIN; CELLS; COMBINATION; EFFICACY; SIZE
- Issue Date
- 2018-04
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- NPG ASIA MATERIALS, v. 10, Page. 197.0-216.0
- Abstract
- Multimodal therapeutic agents based on novel nanomaterials for multidrug resistance have attracted increasing attention in cancer therapy. In this study, we describe the construction of a programmed mesoporous silica-capped gold nanorod covered with nano-selenium overcoat (Se@Au@mSiO(2)) nanoparticles as a multifunctional nanoplatform to incorporate materials with specific chemotherapeutic, chemoprevention, and photoablation/hyperthermia functions that collectively contribute to enhance anticancer efficacy in multidrug-resistant breast cancer. The triple-combination-based nanosized Se@Au@mSiO(2)/DOX effectively accumulates in the tumor and the release of the therapeutic cargo could be remotely manipulated by mild near-infrared (NIR) irradiation. Se@Au@mSiO(2)/DOX notably enhances the cell killing effect through induction of cell apoptosis. In addition, Se@Au@mSiO(2)/DOX inhibits tumor cell growth through cell cycle arrest and induction of apoptosis via suppression of the Src/FAK/AKT signaling pathways. Synergistic Se-photothermal-chemotherapy combination exhibits significant tumor growth suppression and delayed tumor progression in vivo. Immunohistochemistry analysis shows elevated numbers of caspase-3 and PARP-immunolabeled cells and decreased Ki-67 + and CD31 + cancer cells in the tumor mass. No noticeable signs of organ damage or toxicity are observed after treatment with Se@Au@mSiO2/DOX (NIR+), which is further supported by hematology and biochemical analyses. Thus, Se@Au@mSiO2/DOX has potential for the clinical treatment of metastatic breast cancers with little or no adverse effects.
- URI
- https://www.nature.com/articles/s41427-018-0034-5https://repository.hanyang.ac.kr/handle/20.500.11754/182323
- ISSN
- 1884-4049;1884-4057
- DOI
- 10.1038/s41427-018-0034-5
- Appears in Collections:
- COLLEGE OF PHARMACY[E](약학대학) > PHARMACY(약학과) > Articles
- Files in This Item:
- 4493_최한곤.pdfDownload
- Export
- RIS (EndNote)
- XLS (Excel)
- XML